These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29738813)

  • 1. Perfusion mammalian cell culture for recombinant protein manufacturing - A critical review.
    Bielser JM; Wolf M; Souquet J; Broly H; Morbidelli M
    Biotechnol Adv; 2018; 36(4):1328-1340. PubMed ID: 29738813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing.
    O'Flaherty R; Bergin A; Flampouri E; Mota LM; Obaidi I; Quigley A; Xie Y; Butler M
    Biotechnol Adv; 2020 Nov; 43():107552. PubMed ID: 32416132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated continuous production of recombinant therapeutic proteins.
    Warikoo V; Godawat R; Brower K; Jain S; Cummings D; Simons E; Johnson T; Walther J; Yu M; Wright B; McLarty J; Karey KP; Hwang C; Zhou W; Riske F; Konstantinov K
    Biotechnol Bioeng; 2012 Dec; 109(12):3018-29. PubMed ID: 22729761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upstream continuous processing: recent advances in production of biopharmaceuticals and challenges in manufacturing.
    Matanguihan C; Wu P
    Curr Opin Biotechnol; 2022 Dec; 78():102828. PubMed ID: 36332340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
    Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
    J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production.
    Dizon-Maspat J; Bourret J; D'Agostini A; Li F
    Biotechnol Bioeng; 2012 Apr; 109(4):962-70. PubMed ID: 22094920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Different Perspective: How Much Innovation Is Really Needed for Monoclonal Antibody Production Using Mammalian Cell Technology?
    Kelley B; Kiss R; Laird M
    Adv Biochem Eng Biotechnol; 2018; 165():443-462. PubMed ID: 29721583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a new bioprocess scheme using frozen seed train intermediates to initiate CHO cell culture manufacturing campaigns.
    Seth G; Hamilton RW; Stapp TR; Zheng L; Meier A; Petty K; Leung S; Chary S
    Biotechnol Bioeng; 2013 May; 110(5):1376-85. PubMed ID: 23242970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shift to high-intensity, low-volume perfusion cell culture enabling a continuous, integrated bioprocess.
    Gagnon M; Nagre S; Wang W; Hiller GW
    Biotechnol Prog; 2018 Nov; 34(6):1472-1481. PubMed ID: 30298995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fed-Batch CHO Cell Culture for Lab-Scale Antibody Production.
    Fan Y; Ley D; Andersen MR
    Methods Mol Biol; 2018; 1674():147-161. PubMed ID: 28921435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomics as a tool for assessing the scalability of mammalian cell perfusion systems.
    Jayapal KP; Goudar CT
    Adv Biochem Eng Biotechnol; 2014; 139():227-43. PubMed ID: 23949697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Process performance and product quality in an integrated continuous antibody production process.
    Karst DJ; Steinebach F; Soos M; Morbidelli M
    Biotechnol Bioeng; 2017 Feb; 114(2):298-307. PubMed ID: 27497430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrated fed-batch cell culture increases manufacturing capacity without additional volumetric capacity.
    Yang WC; Minkler DF; Kshirsagar R; Ryll T; Huang YM
    J Biotechnol; 2016 Jan; 217():1-11. PubMed ID: 26521697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors.
    De Jesus M; Wurm FM
    Eur J Pharm Biopharm; 2011 Jun; 78(2):184-8. PubMed ID: 21256214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioreactor productivity and media cost comparison for different intensified cell culture processes.
    Xu S; Gavin J; Jiang R; Chen H
    Biotechnol Prog; 2017 Jul; 33(4):867-878. PubMed ID: 27977910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of Raman Spectroscopy in Biopharmaceutical Manufacturing: A Short Review.
    Buckley K; Ryder AG
    Appl Spectrosc; 2017 Jun; 71(6):1085-1116. PubMed ID: 28534676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering death resistance in CHO cells for improved perfusion culture.
    MacDonald MA; Nöbel M; Martínez VS; Baker K; Shave E; Gray PP; Mahler S; Munro T; Nielsen LK; Marcellin E
    MAbs; 2022; 14(1):2083465. PubMed ID: 35737825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Process intensification for the production of rituximab by an inducible CHO cell line.
    Mellahi K; Brochu D; Gilbert M; Perrier M; Ansorge S; Durocher Y; Henry O
    Bioprocess Biosyst Eng; 2019 May; 42(5):711-725. PubMed ID: 30673843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.
    Yang WC; Lu J; Kwiatkowski C; Yuan H; Kshirsagar R; Ryll T; Huang YM
    Biotechnol Prog; 2014; 30(3):616-25. PubMed ID: 24574326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing an ultra-intensified fed-batch cell culture process with greatly improved performance and productivity.
    Xiang S; Zhang J; Yu L; Tian J; Tang W; Tang H; Xu K; Wang X; Cui Y; Ren K; Cao W; Su Y; Zhou W
    Biotechnol Bioeng; 2024 Feb; 121(2):696-709. PubMed ID: 37994547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.